AviaraDx has launched two new oncology tests for classifying metastatic cancer and identifying patients with estrogen receptor (ER) positive breast cancer who are at high risk of recurrence, as well as unlikely to respond favorably to standard adjuvant endocrine therapy.

The two tests are:

• CancerTYPE ID, which assists physicians in diagnosing metastatic cancer types based on a 92-gene expression assay that is capable of classifying 39 tumor types as well as 64 cancer subtypes, according to AviaraDx. The results help clinicians identify the primary tumor site and avoid repetitive imaging and immunohistological procedures in attempting to establish the cancer origin, the company reported. 
• H/I, which assists physicians in determining the optimal treatment for patients with ER positive, node-negative breast cancer by using two newly developed gene-based biomarkers to evaluate the risk of recurrence and probable response to endocrine therapy, according to company.  The test is designed to identify the 10 to 20 percent of ER-positive breast cancers that will relapse within five to 10 years when treated with standard endocrine therapy, AviaraDx said. 

The Carlsbad, Calif.-based AviaraDx also reported that the tests are N.Y. state-approved and available through its CAP-certified CLIA laboratory.  Both can utilize small formalin-fixed and paraffin-embedded tissue samples available from imaging-guided needle biopsies.